Seres Therapeutics (MCRB) Equity Average (2016 - 2025)
Seres Therapeutics (MCRB) has disclosed Equity Average for 11 consecutive years, with $44.0 million as the latest value for Q4 2025.
- Quarterly Equity Average rose 133.18% to $44.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $44.0 million through Dec 2025, up 133.18% year-over-year, with the annual reading at $29.0 million for FY2025, 286.67% up from the prior year.
- Equity Average hit $44.0 million in Q4 2025 for Seres Therapeutics, up from $38.3 million in the prior quarter.
- In the past five years, Equity Average ranged from a high of $159.2 million in Q1 2021 to a low of -$73.4 million in Q2 2024.
- Historically, Equity Average has averaged $38.8 million across 5 years, with a median of $38.8 million in 2022.
- Biggest five-year swings in Equity Average: soared 389.58% in 2021 and later tumbled 943.08% in 2024.
- Year by year, Equity Average stood at $153.6 million in 2021, then plummeted by 74.49% to $39.2 million in 2022, then crashed by 176.54% to -$30.0 million in 2023, then skyrocketed by 162.86% to $18.9 million in 2024, then surged by 133.18% to $44.0 million in 2025.
- Business Quant data shows Equity Average for MCRB at $44.0 million in Q4 2025, $38.3 million in Q3 2025, and $41.7 million in Q2 2025.